A Phase 2 interventional study of EYP001a and Placebo in Hepatitis B, Chronic, sponsored by Enyo Pharma. Terminated at 18 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-11-02.
Sponsored by Enyo Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Hepatitis B, Chronic with a site in Korea, Republic of — 4 open to participants now, 10 under way, 1 of them phase 3. Hepatitis B, Chronic · Korea, Republic of.
Among the 149 studies in Hepatitis B, Chronic with a site in Korea, Republic of, this one is the 120th largest by enrollment of the 126 interventional ones that give a count, is one of 12 that started in 2020, is one of 31 in phase 2, and was the 119th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →4 of the 149 studies in Hepatitis B, Chronic with a site in Korea, Republic of are open now. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in Korea, Republic of, Australia, China and 4 more countries
Ages 18–65
ImmuneMed, Inc. · Sites in Korea, Republic of
Ages 19–64
Yonsei University · Sites in Korea, Republic of
Ages 19+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 38 · Phase 3 22 · Phase 4 50
First in 2002; this study’s year is marked. 12 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 106 across the 126 interventional studies, 269 across the 21 observational. Of the 111 that completed or were terminated, 45 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
104 of 149 have an industry lead sponsor. The 10 most frequent:
Enyo Pharma is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Enyo Pharma has 5 studies filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
3 of the studies in Hepatitis B, Chronic with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04780204Asan Medical CenterEffectiveness of Antiviral Treatment in Cirrhotic Patients With Low-level Hepatitis B Virus DNA Levels | 2027-01 |
| NCT06963710Aligos TherapeuticsA Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) | 2027-03 |
| NCT06537414GlaxoSmithKlineA Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) | 2027-05-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 149 studies in Hepatitis B, Chronic with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, multi-centre, randomized, double-blind, placebo-controlled, Phase 2a experimental study of oral FXR modulator EYP001a/placebo combined with NAs in virologically suppressed CHB patients to improve functional cure rates.
A total of 49 eligible patients will be enrolled and randomized at approximately 14 study sites. Patients will be randomized prior to study drug (EYP001a or placebo and NA) administration on Day 1 in the ratio of 3:1 into 2 arms:
The maximum total engagement duration for eligible patients in this study is up to 370 days: 90 days screening, 112 days (16 weeks) treatment period and 168 days (24 weeks) follow-up.
Patients enrolled in the study will be assessed as outpatients. Patient screening will occur no more than 90 days prior to the Day 1 visit. Eligible patients will undergo further assessments on Day 1 to qualify for study drug administration on Day 1.
The visits during the study are planned as below:
Main Inclusion Criteria:
\<LLOQ and serum HBsAg >100 IU/mL
Main Exclusion Criteria:
Has any of the following exclusionary laboratory results at screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental Arm: EYP001a Dose A QD + NA daily (37 patients)
Drug: EYP001a · Drug: Nucleotide analogue (Entecavir or Tenofovir Disoproxil)
Control Arm: Placebo + NA daily (12 patients)
Drug: Placebo · Drug: Nucleotide analogue (Entecavir or Tenofovir Disoproxil)
Oral tablets
Oral tablets
Oral tablets
HBsAg Change (Δ log10) From Day 1 to Week 16 of Treatment
Efficacy of Vonafexor on top of NA assessed as HBsAg decline (Δ log10) from Day 1 to Week 16 of treatment
Time frame: LS mean at week 16 (Day 1, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12, Week 14, and Week 16)
Virologic Failure Rate
Virologic failure rate (breakthrough)2 of HBV-DNA (% patients with a confirmed quantifiable HBV DNA increase of ≥ 1log10 HBV DNA copies/mL above LLOQ3) assessed at Week 16 of treatment period and Weeks 20, 28 and 40 during follow-up period
Time frame: 40 weeks
| Milestone | Experimental Arm | Control Arm |
|---|---|---|
| Started | 19 | 7 |
| Completed | 19 | 6 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Efficacy of Vonafexor on top of NA assessed as HBsAg decline (Δ log10) from Day 1 to Week 16 of treatment
| log10 IU/mL | Experimental Arm | Control Arm |
|---|---|---|
| HBsAg Change (Δ log10) From Day 1 to Week 16 of Treatment | -0.029 ± 0.0195 | -0.066 ± 0.0348 |
Virologic failure rate (breakthrough)2 of HBV-DNA (% patients with a confirmed quantifiable HBV DNA increase of ≥ 1log10 HBV DNA copies/mL above LLOQ3) assessed at Week 16 of treatment period and Weeks 20, 28 and 40 during follow-up period
| participants | Experimental Arm | Control Arm |
|---|---|---|
| Week 16 | 0 | 0 |
| Week 20 | 0 | 0 |
| Week 28 | 0 | 0 |
| Week 40 | 0 | 0 |
Collected over After the first dose of study drug until W40. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental Arm | 0/19 (0%) | 0/19 (0%) | 17/19 (89.5%) |
| Control Arm | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Event | Experimental Arm | Control Arm |
|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 15/19 | 1/7 |
| DiarrhoeaGastrointestinal disorders | 3/19 | 0/7 |
| Serum ferritin decreasedInvestigations | 0/19 | 1/7 |
| White blood cell count decreasedInvestigations | 0/19 | 1/7 |
| Atrioventricular block first degreeCardiac disorders | 0/19 | 1/7 |
| NeutropeniaBlood and lymphatic system disorders | 0/19 | 1/7 |
| Abdominal pain lowerGastrointestinal disorders | 0/19 | 1/7 |
| Hiatus herniaGastrointestinal disorders | 0/19 | 1/7 |
| OesophagitisGastrointestinal disorders | 0/19 | 1/7 |
| NauseaGastrointestinal disorders | 2/19 | 0/7 |
| Age, Continuous(years) | Experimental Arm | Control Arm | Total |
|---|---|---|---|
| Geometric mean | 45.16 ± 8.32 | 46.29 ± 8.46 | 45.46 ± 8.20 |
| Sex: Female, Male(Participants) | Experimental Arm | Control Arm | Total |
|---|---|---|---|
| Female | 5 | 1 | 6 |
| Male | 14 | 6 | 20 |
| Race/Ethnicity, Customized(participants) | Experimental Arm | Control Arm | Total |
|---|---|---|---|
| Asian | 19 | 5 | 24 |
| Black or African American | 0 | 1 | 1 |
| White | 0 | 1 | 1 |
| Weight(kg) | Experimental Arm | Control Arm | Total |
|---|---|---|---|
| Geometric mean | 68.821 ± 11.293 | 82.857 ± 21.084 | 72.600 ± 15.454 |
| Height(cm) | Experimental Arm | Control Arm | Total |
|---|---|---|---|
| Geometric mean | 168.763 ± 9.333 | 172.529 ± 11.342 | 169.777 ± 9.823 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2020 to primary completion in Jun 2021, 13 months.
Results were first posted in Oct 2022, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EYP001A
Enyo Pharma